Valneva has been granted a patent for a method to produce infectious paramyxovirus particles using a specific duck cell line. The process involves transfecting the cells with vectors containing paramyxovirus nucleic acid sequences and essential proteins, enabling the rescue and propagation of various paramyxoviruses for medical applications. GlobalData’s report on Valneva gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Valneva, Anti-viral antigen-based compositions was a key innovation area identified from patents. Valneva's grant share as of July 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Method for producing infectious paramyxovirus particles in duck cells
The granted patent US12053518B2 outlines a method for producing infectious paramyxovirus particles through a series of transfection and culturing steps involving a duck cell line. The process begins with the transfection of the cell line using a vector that contains a paramyxovirus nucleic acid sequence regulated by a T7 promoter, along with a T7 RNA polymerase expression vector and three additional expression vectors that encode the paramyxovirus phosphoprotein, nucleoprotein, and polymerase. The transfected cells are then cultured under specific conditions to facilitate the production of infectious paramyxovirus particles. The method allows for the incorporation of various modifications, including the addition of foreign antigens and the use of different paramyxovirus strains.
Further claims within the patent detail the versatility of the method, allowing for the production of wild-type, chimeric, or recombinant paramyxoviruses. The nucleic acid sequence can be engineered to include restriction enzyme sites for the insertion of heterologous coding sequences, which can encode antigens from viral pathogens or proteins with therapeutic potential. Specific examples include coding sequences for human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) antigens, as well as the fusion (F) and matrix (M) proteins from these viruses. The patent also specifies the use of Newcastle Disease Virus (NDV) nucleic acids, including various strains, to create virus-like particles or recombinant genomes, enhancing the potential applications of this method in vaccine development and virology research.
To know more about GlobalData’s detailed insights on Valneva, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
